[1]CAMIDGE DR,PAO W,SEQUIST LV,et al.Acquired resistance to TKIs in solid tumours:learning from lung cancer［J］.Nat Rev Clin Oncol,2014,11(8):473-481.
[2]HUANG MY,JIANG XM,WANG BL,et al.Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer:strategies and mechanisms［J］.Pharmacol Ther，2021,219:107694.
[3]ZHOU F,QIAO M,ZHOU C.The cutting-edge progress of immune-checkpoint blockade in lung cancer［J］.Cell Mol Immunol，2021,18(2):279-293.
[4]QU J,MEI Q,LIU L,et al.The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer［J］.Ther Adv Med Oncol,2021,13:1758835921992968.
[5]CARBONE DP,RECK M,PAZ-ARES L,et al.First-line nivolumab in stage iv or recurrent non-small-cell lung cancer［J］.N Engl J Med,2017,376(25):2415-2426.
[6]BRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer［J］.N Engl J Med,2015,373(2):123-135.
[7]BORGHAEI H,PAZ-ARES L,HORN L,et al.Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer［J］.N Engl J Med,2015,373(17):1627-1639.
[8]PAI-SCHERF L,BLUMENTHAL GM,LI H,et al.FDA approval summary:Pembrolizumab for treatment of metastatic non-small cell lung cancer:first-line therapy and beyond［J］.Oncologist,2017,22(11):1392-1399.
[9]WU YL,LU S,CHENG Y,et al.Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC:checkMate 078 randomized phase Ⅲ clinical trial［J］.Journal of Thoracic Oncology,2019,14(5):867-875.
[10]GARON EB,HELLMANN MD,RIZVI NA,et al.Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab:Results from the phase Ⅰ Keynote-001 study［J］.Journal of Clinical Oncology,2019,37(28):2518-2527.
[11]NOSAKI K,SAKA H,HOSOMI Y,et al.Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer:Pooled analysis from the Keynote010,Keynote-024,and Keynote-042 studies ［J］.Lung Cancer,2019,135:188-195.
[12]GANDHI L,RODRIGUEZ-ABREU D,GADGEEL S,et al.Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer［J］.N Engl J Med,2018,378(22):2078-2092.
[13]RITTMEYER A,BARLESI F,WATERKAMP D,et al.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK):a phase 3,open-label,multicentre randomised controlled trial［J］.Lancet,2017,389(10066):255-265.
[14]ANTONIA SJ.Durvalumab afterchemoradiotherapy in stage Ⅲ non-small-cell lung cancer［J］.N Engl J Med,2019,380(10):990.
[15]PAZ-ARES L,URBAN L,AUDIGIER-VALETTE C,et al.CheckMate 817:safety of flat-dose nivolumab plus weight-based ipilimumab for the first-line treatment of advanced NSCLC［J］.Journal of Thoracic Oncology,2018,13(10):S493.
[16]RECK M,SCHENKER M,LEE KH,et al.Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden:patient-reported outcomes result from the randomised,open-label,phase Ⅲ CheckMate 227 trial［J］.Eur J Cancer,2019,116:137-147.
[17] HSU ML,NAIDOO J.Principles ofimmunotherapy in non-small cell lung cancer［J］.Thorac Surg Clin,2020,30(2):187-198.
[18]OVERMAN MJ,MCDERMOTT R,LEACH JL,et al.Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142):an open-label,multicentre,phase 2 study［J］.Lancet Oncology,2017,18(9):1182-1191.
[19]NEBOT-BRAL L,COUTZAC C,KANNOUCHE PL,et al.Why is immunotherapy effective (or not)in patients with MSI/MMRD tumors［J］.Bull Cancer,2019,106(2):105-113.
[20]HIRSCH D,GAISER T,MERX K,et al.Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system［J］.J Cancer Res Clin Oncol,2021,147(1):263-273.
[21]TOOR SM,SASIDHARAN NAIR V,MURSHED K,et al.Tumor-infiltrating lymphoid cells in colorectal cancer patients with varying disease stages and microsatellite instability-high/stable tumors［J］.Vaccines (Basel),2021,9(1):64.
[22]READY N,HELLMANN MD,AWAD MM,et al.First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568):outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers［J］.J Clin Oncol,2019,37(12):992-1000.
[23]GANDARA DR,PAUL SM,KOWANETZ M,et al.Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab ［J］.Nat Med,2018,24(9):1441-1448.
[24]RASHDAN S,MINNA JD,GERBER DE.Lung cancer immunotherapy biomarkers:refine not reject［J］.Lancet Respir Med,2018,6(6):403.
[25]ZHAO Y,LEE CK,LIN CH,et al.PD-L1:CD80 cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways［J］.Immunity,2019,17,51(6):1059-1073.
[26]KAMPHORST AO,WIELAND A,NASTI T,et al.Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent［J］.Science,2017,355(6332):1423-1427.
[27] HAN J,DUAN J,BAI H,et al.TCR repertoire diversity of peripheral PD-1+CD8+T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer［J］.Cancer Immunol Res,2020,8(1):146-154.
[28]ROUTY B,LE CHATELIER E,DEROSA L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors ［J］.Science,2018,359(6371):91-97.
[29]DATAR I,SANMAMED MF,WANG J,et al.Expression analysis and significance of PD-1,LAG-3,and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis［J］.Clin Cancer Res,2019,25(15):4663-4673.
[30]AYERS M,LUNCEFORD J,NEBOZHYN M,et al.IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade［J］.J Clin Invest,2017,127(8):2930-2940.
[31]FEHRENBACHER L,SPIRA A,BALLINGER M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre,open-label,phase 2 randomised controlled trial［J］.Lancet,2016,387(10030):1837-1846.
[32]LAURA M,EDOUARD A,ROBERTO F,et al.Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer［J］.JAMA Oncology,2018,4(3):351-357.
[33]JIANG P,GU S,PAN D,et al.Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response［J］.Nat Med,2018,24(10):1550-1558.
[34]AUSLANDER N,ZHANG G,LEE JS,et al.Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma ［J］.Nat Med,2018,24(10):1545-1549.
[35]HOSOYA K,FUJIMOTO D,MORIMOTO T,et al.Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors［J］.Clin Lung Cancer,2020,21(4):e315-e328.
[36]SUN R,LIMKIN EJ,VAKALOPOULOU M,et al.A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy:an imaging biomarker,retrospective multicohort study［J］.Lancet Oncol,2018,19(9):1180-1191.
[37]JIANG Z,LIU Z,LI M,et al.Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment［J］.E Bio Medicine,2019,42:431-442.
[38]NARDUCCI MG,TOSI A,FREZZOLINI A,et al.Reduction of tlymphoma cells and immunological invigoration in a patient concurrently affected by melanoma and sezary syndrome treated with nivolumab［J］.Front Immunol,2020,11:579894.